| Literature DB >> 9486924 |
A Menéndez1, E Svarch, G Martínez, P Hernández.
Abstract
A 10-year-old boy with acute promyelocytic leukemia (APL) was treated with all-trans-retinoic acid (ATRA) at a dose of 60 mg/m2/day. Recombinant erythropoietin was also used. The patient parents and other relatives, all Jehova's Witnesses, refused any type of hemotherapy. After 43 days of ATRA treatment complete remission was obtained without the use of hemotherapy. This case exemplifies the advantages provided by ATRA treatment in APL.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9486924 DOI： 10.1007/s002770050359
Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673